ECOG-ACRIN 5508: Pemetrexed, bevacizumab or the combination as maintenance therapy for advanced non-squamous NSCLC.

Suresh S. Ramalingam,Suzanne E. Dahlberg,Chandra P. Belani,Joel N. Saltzman,Gopakumar S. Nambudiri,John McCann,Jerome D. Winegarden,Mohammed A. Kassem,Mohamed K. Mohamed,Jan M. Rothman,Alan P. Lyss,Leora Horn,Tom Stinchcombe,Joan H. Schiller

ECOG-ACRIN 5508: Pemetrexed, bevacizumab or the combination as maintenance therapy for advanced non-squamous NSCLC.

2019

Suresh S. Ramalingam
Suzanne E. Dahlberg
Chandra P. Belani
Joel N. Saltzman
Gopakumar S. Nambudiri
John McCann
Jerome D. Winegarden
Mohammed A. Kassem
Mohamed K. Mohamed
Jan M. Rothman
Alan P. Lyss
Leora Horn
Tom Stinchcombe
Joan H. Schiller

9002Background: Maintenance therapy is a standard approach for advanced non-squamous NSCLC. Pemetrexed or bevacizumab are considered evidence-based options. The combination of bevacizumab and pemet...

Keywords:

Pemetrexed
Bevacizumab
Oncology
Maintenance therapy
Pathology
Internal medicine
Medicine
non squamous

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations